Body mass index and prognosis in HER2-positive metastatic breast cancer patients

被引：0

作者：

Poletto, E. ^{[1
]}

Minisini, A. M. ^{[1
]}

Ferreira, A. ^{[2
]}

Matteo, L. ^{[3
]}

Poggio, F. ^{[3
]}

Sottotetti, F. ^{[4
]}

Montemurro, F. ^{[5
]}

Pozzi, E. ^{[4
]}

Rossi, V. ^{[5
]}

Risi, E. ^{[6
]}

Dellepiane, C. ^{[7
]}

Sini, V. ^{[8
]}

Ziliani, S. ^{[9
]}

Minuti, G. ^{[10
]}

Mura, S. ^{[11
]}

Grasso, D. ^{[12
]}

Bertolini, I. ^{[13
]}

Del Mastro, L. ^{[3
]}

Puglisi, F. ^{[14
]}

机构：

[1] Azienda Osped Santa Maria Della Misericordia, Dept Oncol, Udine, Italy

[2] Hosp Santa Maria, Inst Med Mol, Dept Med Oncol, Lisbon, Portugal

[3] IRCCS AOU San Martino IST, UO Oncol Med 2, Genoa, Italy

[4] Fdn Maugeri IRCCS, Unita Dipartimentale Oncol Med, Pavia, Italy

[5] Ist Candiolo IRCCS, Unit Invest Clin Oncol, Candiolo, Italy

[6] Univ Roma La Sapienza, Dept Radiol Oncol & Human Pathol, Oncol Unit B, I-00185 Rome, Italy

[7] IRCCS AOU San Martino IST, Clin Oncol Med, Genoa, Italy

[8] Univ Roma La Sapienza, St Andrea Hosp, Oncol Unit, I-00185 Rome, Italy

[9] Osped San Paolo, Oncol Med, Savona, Italy

[10] Ist Tumori Toscano, Dept Med Oncol, Livorno, Italy

[11] Osped Santissima Annunziata, Dept Med Oncol, Sassari, Italy

[12] IRCCS San Matteo Univ Hosp Fdn, Med Oncol, Pavia, Italy

[13] Azienda Osped Univ Pisana, Dept Oncol, Polo Oncol, Pisa, Italy

[14] Univ Hosp, Dept Oncol, Udine, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)30811-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1861

引用

页码：S285 / S286

页数：2

共 50 条

[11] HER2-positive metastatic breast cancer: A changing scenario
Mustacchi, G.
Biganzoli, L.
Pronzato, P.
Montemurro, F.
Dambrosio, M.
Minelli, M.
Molteni, L.
Scaltriti, L.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 95 (01) : 78 - 87
[12] Overcoming resistance in Her2-positive metastatic breast cancer
Oksuzoglu, Omur Berna
LEUKEMIA RESEARCH, 2018, 73 : S13 - S13
[13] Updates in Treatment of HER2-positive Metastatic Breast Cancer
Avelino, Alzira R. M.
Pulipati, Soumya
Jamouss, Kevin
Bhardwaj, Prarthna V.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, 25 (12) : 1471 - 1481
[14] Trastuzumab emtansine in HER2-positive metastatic breast cancer
Montemurro, Filippo
LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
[15] The changing treatment of metastatic her2-positive breast cancer
Mitsogianni, Maria
Trontzas, Ioannis P.
Gomatou, Georgia
Ioannou, Stephanie
Syrigos, Nikolaos K.
Kotteas, Elias A.
ONCOLOGY LETTERS, 2021, 21 (04)
[16] HER2-Positive Metastatic Breast Cancer: A Comprehensive Review
Exman, Pedro
Tolaney, Sara M.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 40 - 50
[17] Optimizing treatment of HER2-positive metastatic breast cancer
Jones, AL
Leyland-Jones, B
SEMINARS IN ONCOLOGY, 2004, 31 (05) : 29 - 34
[18] Advancing outcomes of metastatic HER2-positive breast cancer
Chumsri, Saranya
LANCET, 2023, 401 (10390): : 1746 - 1747
[19] Margetuximab for the treatment of HER2-positive metastatic breast cancer
Tarantino, Paolo
Morganti, Stefania
Uliano, Jacopo
Giugliano, Federica
Crimini, Edoardo
Curigliano, Giuseppe
EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (02) : 127 - 133
[20] Pertuzumab biosimilar in HER2-positive metastatic breast cancer
Lorenz, Judith
GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (01) : 21 - 21

← 1 2 3 4 5 →